drugset

drugset / Trial / NCT05297864

PARP Inhibition for Gliomas (PI-4G or π4g)

NCT05297864 ↗

Phase 2 Terminated 15 enrolled University of Oklahoma GlaxoSmithKline · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

Timeline

Start: 2022-06-09
Primary completion: 2023-11-14
Completion: 2024-02-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Niraparib	Small molecule	300 mg	Oral

Indications